- Home
- VSTM vs XBIT Comparison
VSTM vs XBIT Comparison
Compare VSTM & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- XBIT
- Stock Information
- Founded
- VSTM 2010
- XBIT 2005
- Country
- VSTM United States
- XBIT United States
- Employees
- VSTM N/A
- XBIT N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- XBIT Pharmaceuticals and Biotechnology
- Sector
- VSTM Health Care
- XBIT Health Care
- Exchange
- VSTM Nasdaq
- XBIT Nasdaq
- Market Cap
- VSTM 239.9M
- XBIT 194.5M
- IPO Year
- VSTM 2012
- XBIT 2015
- Fundamental
- Price
- VSTM $5.39
- XBIT $3.86
- Analyst Decision
- VSTM Strong Buy
- XBIT
- Analyst Count
- VSTM 8
- XBIT 0
- Target Price
- VSTM $12.43
- XBIT N/A
- AVG Volume (30 Days)
- VSTM 2.4M
- XBIT 94.1K
- Earning Date
- VSTM 03-13-2025
- XBIT 03-14-2025
- Dividend Yield
- VSTM N/A
- XBIT N/A
- EPS Growth
- VSTM N/A
- XBIT N/A
- EPS
- VSTM N/A
- XBIT N/A
- Revenue
- VSTM $10,000,000.00
- XBIT N/A
- Revenue This Year
- VSTM N/A
- XBIT N/A
- Revenue Next Year
- VSTM $117.91
- XBIT N/A
- P/E Ratio
- VSTM N/A
- XBIT N/A
- Revenue Growth
- VSTM N/A
- XBIT N/A
- 52 Week Low
- VSTM $2.10
- XBIT $3.51
- 52 Week High
- VSTM $14.22
- XBIT $9.96
- Technical
- Relative Strength Index (RSI)
- VSTM 53.22
- XBIT 34.54
- Support Level
- VSTM $5.08
- XBIT $3.64
- Resistance Level
- VSTM $6.02
- XBIT $4.00
- Average True Range (ATR)
- VSTM 0.68
- XBIT 0.30
- MACD
- VSTM -0.06
- XBIT 0.05
- Stochastic Oscillator
- VSTM 50.79
- XBIT 27.18
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.